The National Cancer Institute (NCI) seeks licensees and/or research co-development partners for a collection of novel T-cell receptors (TCRs) that target the Epstein Barr Virus Latent Membrane Protein 2 (EBV-LMP2). The TCRs are being developed as therapeutics for treatment of lymphomas and epithelial cancers.
There remains a need for effective immunotherapies to treat solid tumors as well as hematological malignancies. Researchers at the National Cancer Institute (NCI) have designed novel chimeric adaptor proteins (CAPs) consisting of signaling molecules downstream of the T cell receptor (TCR) for use in T cell-mediated immunotherapy. NCI is seeking parties interested in licensing and/or co-developing CAPs that can be used in immunotherapy for treating cancer, including both hematological and solid malignancies.
Researchers at the National Institutes of Health have identified a collection of TCRs that specifically target mutated KRAS antigen. These TCRs exclusively recognize the G12D or G12V variants of mutated KRAS, which are common hotspot driver mutations expressed by a variety of epithelial cancers, including pancreatic, colorectal and lung cancer. The mutated KRAS variants are recognized by the TCRs in the context of HLA-A*11:01 or HLA-C*08:02. These TCRs can be used for a variety of experimental therapeutic, diagnostic and research applications.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for small molecules that inhibit histone lysine demethylases (KDMs). These compounds may be effective therapeutics for Rhabdomyosarcoma (RMS) and other cancers.
The National Cancer Institute (NCI) seeks research, co-development, or licensing partners for software that uses computational approaches in cancer diagnosis. NCI researchers have recently developed a computational approach for detecting, quantifying, and mapping Mitotic Hotspots in whole slide images of tumor tissue. This technology has demonstrated high reproducibility that is unaffected by diagnostic skill or fatigue, allowing standardization of tumor cell proliferation assessment across institutions.
National Cancer Institute (NCI) researchers have developed a novel software tool for uniform recording of Mitotic Figure (MF) counts via conventional and/or digital microscopy. With this technology, diagnostic centers can standardize electronic recording, summation, and transcription of clinical data during surgical pathology examination. NCI seeks licensing partners to further develop this application for use in diagnosis and detection of malignant cancers.
Researchers at the National Cancer Institute (NCI) and the National Heart Lung and Blood Institute (NHLBI) have discovered a method of improving adoptive T cell therapy by preconditioning CD8+ T cells with a lactate dehydrogenase (LDH) inhibitor. NCI seeks research co-development partners and/or licensees for clinical evaluation of the invention.
Scientists at the National Eye Institute (NEI) have developed an embryo culture chamber, which can be used to culture and image embryos. The chamber allows for the continuous imaging of the embryo for the culture period. NEI seeks research collaborations and/or licensees for the development of this culture and imaging chamber for murine embryos.
Researchers at the National Cancer Institute (NCI) have developed aryl hydantoin heterocycles that target the androgen receptor (AR). NCI seeks research co-development partners and/or licensees to develop these compounds as therapeutics for prostate cancer. As these compounds consist of both AR agonists and antagonists, they may also be effective therapeutics for androgen dysfunctional disorders, such as androgen deficiency disorders or hyperandrogenism.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development of a human immunodeficiency virus (HIV) vaccine targeting HIV conserved elements, including the V1V2 region.